NYSE:NVO - Novo Nordisk A/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $48.05 +0.40 (+0.84 %) (As of 01/18/2019 04:00 PM ET)Previous Close$47.65Today's Range$47.80 - $48.4952-Week Range$41.23 - $58.37Volume1.80 million shsAverage Volume1.61 million shsMarket Capitalization$114.53 billionP/E Ratio20.53Dividend Yield1.40%Beta0.66 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration; and a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S has a collaboration agreement with Embark Biotech ApS for the discovery of novel treatments for obesity and its associated metabolic pathologies. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Receive NVO News and Ratings via Email Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVO Previous Symbol CUSIPN/A Webwww.novonordisk.com Phone45-4444-8888Debt Debt-to-Equity RatioN/A Current Ratio1.10 Quick Ratio0.77Price-To-Earnings Trailing P/E Ratio20.53 Forward P/E Ratio19.45 P/E Growth2.11 Sales & Book Value Annual Sales$16.96 billion Price / Sales6.92 Cash Flow$2.6314 per share Price / Cash Flow18.26 Book Value$3.10 per share Price / Book15.50Profitability EPS (Most Recent Fiscal Year)$2.34 Net Income$5.79 billion Net Margins34.94% Return on Equity81.50% Return on Assets38.73%Miscellaneous Employees42,076 Outstanding Shares2,443,528,000Market Cap$114.53 billion OptionableOptionable Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions What is Novo Nordisk A/S's stock symbol? Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO." How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S? Novo Nordisk A/S declared a special dividend on Thursday, August 9th. Investors of record on Monday, August 20th will be paid a dividend of $0.4669 per share on Tuesday, August 28th. This represents a dividend yield of 1.72%. The ex-dividend date of this dividend is Friday, August 17th. View Novo Nordisk A/S's Dividend History. How will Novo Nordisk A/S's stock buyback program work? Novo Nordisk A/S declared that its Board of Directors has initiated a share buyback plan on Friday, February 2nd 2018, which allows the company to repurchase shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its stock is undervalued. How were Novo Nordisk A/S's earnings last quarter? Novo Nordisk A/S (NYSE:NVO) posted its earnings results on Thursday, November, 1st. The company reported $0.58 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.58. The business had revenue of $4.31 billion for the quarter, compared to analyst estimates of $4.11 billion. Novo Nordisk A/S had a return on equity of 81.50% and a net margin of 34.94%. View Novo Nordisk A/S's Earnings History. When is Novo Nordisk A/S's next earnings date? Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Novo Nordisk A/S. What guidance has Novo Nordisk A/S issued on next quarter's earnings? Novo Nordisk A/S issued an update on its FY 2018 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $17.425-17.592 billion, compared to the consensus revenue estimate of $17.33 billion. What is the consensus analysts' recommendation for Novo Nordisk A/S? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S. Has Novo Nordisk A/S been receiving favorable news coverage? Headlines about NVO stock have been trending positive recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a coverage optimism score of 2.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. Who are some of Novo Nordisk A/S's key competitors? Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG). Who are Novo Nordisk A/S's key executives? Novo Nordisk A/S's management team includes the folowing people: Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 52)Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 58)Mr. Jesper Brandgaard, Exec. VP and Head of Biopharm & Legal Affairs (Age 55)Ms. Liselotte Hyveled, Former Project VP for Faster-Acting Insulin Aspart & Prandial Bioedge Projects - Insulin & Director (Age 52)Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 46) Who are Novo Nordisk A/S's major shareholders? Novo Nordisk A/S's stock is owned by a number of of institutional and retail investors. Top institutional investors include Saratoga Research & Investment Management (0.06%), Alta Capital Management LLC (0.04%), Scout Investments Inc. (0.01%), Ferguson Wellman Capital Management Inc. (0.01%), JLB & Associates Inc. (0.01%) and Smithbridge Asset Management Inc. DE (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S. Which institutional investors are selling Novo Nordisk A/S stock? NVO stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Saratoga Research & Investment Management, Alta Capital Management LLC, JLB & Associates Inc., Gradient Investments LLC, Kavar Capital Partners LLC, Pennsylvania Trust Co and Bath Savings Trust Co. View Insider Buying and Selling for Novo Nordisk A/S. Which institutional investors are buying Novo Nordisk A/S stock? NVO stock was acquired by a variety of institutional investors in the last quarter, including Capital Insight Partners LLC, Douglas Lane & Associates LLC, Quadrant Capital Group LLC, Ferguson Wellman Capital Management Inc., Personal Capital Advisors Corp, Ipswich Investment Management Co. Inc., Moody National Bank Trust Division and Smithbridge Asset Management Inc. DE. View Insider Buying and Selling for Novo Nordisk A/S. How do I buy shares of Novo Nordisk A/S? Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novo Nordisk A/S's stock price today? One share of NVO stock can currently be purchased for approximately $48.05. How big of a company is Novo Nordisk A/S? Novo Nordisk A/S has a market capitalization of $114.53 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk A/S employs 42,076 workers across the globe. What is Novo Nordisk A/S's official website? The official website for Novo Nordisk A/S is http://www.novonordisk.com. How can I contact Novo Nordisk A/S? Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected] MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 276 (Vote Outperform)Underperform Votes: 363 (Vote Underperform)Total Votes: 639MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?